Gentamicin

Summary

Gentamicin (CHEMBL6067485) is an approved small molecule (ATC J01GB03) targeting TRPA1 and TRPV5; indicated across 28 conditions including bacterial infectious disease and eye infectious disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01GB03 (+4 more)
• Targets: 2 (TRPA1, TRPV5)
• Indications: 28 conditions
• Clinical trials: 99

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6067485
Name	Gentamicin
Type	Small molecule
Max phase	4
ATC	J01GB03, D06AX07, S03AA06, S01AA11, S02AA14

Also known as: Gentamicin, Gentamicina, Gentamicine, Gentamycin, Lyramycin, Oksitselanim, Septigen, Uromycine, gentamycin, gentamicin, Gemtamycin, gentamicine

Parent form; salt/anhydrous children: CHEMBL6067484

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
TRPA1	TRPA1	Antagonist	5.2	0.1%	O75762
TRPV5	TRPV5	Inhibition	6	0%	Q9NQA5

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Dihydrofolate reductase, Dihydrofolate reductase, Bacterial 70S ribosome, Xaa-Pro dipeptidase.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P02358	7.55	IC50	28	nM	CHEMBL_ACT_3338450

Target pathways

Aggregated over 2 target gene(s): TRPA1, TRPV5.

Top Reactome pathways

1 total, by targets touching each:

Pathway	Targets	Genes
TRP channels	2	TRPA1, TRPV5

Dominant GO biological processes

GO term	Targets
monoatomic ion transport	2
protein homotetramerization	2
calcium ion transmembrane transport	2
calcium ion transmembrane import into cytosol	2
calcium ion transport	2
monoatomic ion transmembrane transport	2
transmembrane transport	2
intracellular calcium ion homeostasis	1
cell surface receptor signaling pathway	1
response to cold	1
response to xenobiotic stimulus	1
urinary bladder smooth muscle contraction	1
sensory perception of pain	1
cellular response to heat	1
positive regulation of insulin secretion involved in cellular response to glucose stimulus	1

Indications & clinical

Indications

28 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
eye infectious disorder	4	MONDO:0043885	EFO:1001888
cat-scratch disease	3	MONDO:0005692	EFO:0007195
rectal cancer	3	MONDO:0006519	EFO:1000657
breast neoplasm	3	MONDO:0021100	MONDO:0007254
colonic neoplasm	3	MONDO:0005401	MONDO:0021063
plague	3	MONDO:0019095	EFO:0009425
nephrolithiasis	3	MONDO:0008171	EFO:0004253
leishmaniasis	2	MONDO:0011989	EFO:0005044
cutaneous leishmaniasis	2	MONDO:0005446	EFO:0005046
Meniere disease	2	MONDO:0007972	EFO:0006862
folliculitis	2	MONDO:0006552	EFO:1000702
chorioamnionitis	2	MONDO:0000409	EFO:0009948
cystic fibrosis	2	MONDO:0009061	MONDO:0009061
urinary tract infection	2	MONDO:0100338	EFO:0003103
neoplasm	2	MONDO:0005070	MONDO:0004992
epidermolysis bullosa dystrophica	1	MONDO:0006543	MONDO:0009179
atopic eczema	1	MONDO:0004980	EFO:0000274
Duchenne muscular dystrophy	1	MONDO:0010679	MONDO:0010311
osteomyelitis	0	MONDO:0005246	EFO:0003102

8 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 99.

Phase distribution

Phase	Trials
Not specified	30
PHASE4	27
PHASE3	17
PHASE2/PHASE3	8
PHASE2	8
PHASE1	5
PHASE1/PHASE2	3
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05157126	PHASE4	RECRUITING	Gentamicin Open Tibia Study
NCT06332040	PHASE4	RECRUITING	Gentamicin Bladder Instillation on CAUTI
NCT06712641	PHASE4	RECRUITING	Aminoglycosides in Early Sepsis
NCT06814223	PHASE4	RECRUITING	Using Antibiotics to Prevent Infections in Hemodialysis Patients During Catheter Placement
NCT07220967	PHASE4	RECRUITING	A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement
NCT07563504	PHASE4	NOT_YET_RECRUITING	PROMab Trial: Ampicillin With or Without Gentamicin for Term Prelabour Rupture of Membranes
NCT00294502	PHASE4	COMPLETED	Antibiotic Lock Solutions in the Prevention of Catheter Related Bacteremia
NCT00398658	PHASE4	COMPLETED	Prophylaxis of Acute Post-Traumatic Bacterial Endophthalmitis
NCT00480376	PHASE4	UNKNOWN	Ofloxacin vs. Gentamicin as Prophylaxis Prior Transrectal Biopsy of Prostate
NCT00638157	PHASE4	TERMINATED	Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)
NCT00749866	PHASE4	COMPLETED	Long Term Nebulised Gentamicin in Patients With Bronchiectasis
NCT00751374	PHASE4	UNKNOWN	Topical Gentamicin Cream Versus Alternating Gentamicin and Mupirocin Cream in Peritoneal Dialysis
NCT00926796	PHASE4	COMPLETED	Efficacy of Combination Therapies for Gonorrhea Treatment
NCT01247909	PHASE4	COMPLETED	Infant Severe Sepsis and Bacterial Meningitis in Malawi
NCT01273818	PHASE4	COMPLETED	Effectiveness of Topical Antibiotic Prophylaxis in Inguinal Hernia Repair
NCT01659866	PHASE4	COMPLETED	Antibiotic Prophylaxis for Transrectal Prostate Biopsy
NCT01761487	PHASE4	UNKNOWN	SDD for Eradicating CRKP Carriage
NCT01884467	PHASE4	UNKNOWN	Gentamicin Bladder Instillation Trial
NCT01982864	PHASE4	TERMINATED	Pharmacokinetics of an Aminoglycoside in Hemodialysis Patients.
NCT02384200	PHASE4	COMPLETED	A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Kidney Stone Surgery (Percutaneous Nephrolithotomy [PCNL])
NCT02415257	PHASE4	WITHDRAWN	Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function
NCT02848820	PHASE4	UNKNOWN	Initial Non-operative Treatment Strategy Versus Appendectomy Treatment Strategy for Simple Appendicitis in Children
NCT02926846	PHASE4	COMPLETED	IV Antibiotics With Lavage for Severe PD Peritonitis
NCT03299387	PHASE4	WITHDRAWN	INtravesical Antimicrobial Agents v STANDard Oral Antibiotics for the Treatment of Acute UTI in Women With rUTI
NCT03560232	PHASE4	TERMINATED	Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens
NCT03997266	PHASE4	COMPLETED	NICU Antibiotics and Outcomes Trial
NCT06332781	PHASE4	COMPLETED	Intravesical Gentamicin to Prevent Recurrent UTI
NCT05766670	PHASE3	RECRUITING	Intramedullary Calcium Sulfate Antibiotic Depot
NCT05977400	PHASE3	NOT_YET_RECRUITING	NICU Antibiotics and Outcomes (NANO) Follow-up Study
NCT06387147	PHASE3	RECRUITING	ORal Antibiotics in Acute Mesenteric Ischemia
NCT06489431	PHASE3	ACTIVE_NOT_RECRUITING	Irrisept vs Traditional Antibiotic Irrigation for Virgin Penile Prosthesis Placement
NCT00128466	PHASE2/PHASE3	COMPLETED	Treatment and Diagnosis of Plague
NCT00189384	PHASE3	UNKNOWN	Efficacy Study of Community-Based Treatment of Serious Bacterial Infections in Young Infants
NCT00802529	PHASE2/PHASE3	COMPLETED	Transtympanic Gentamicin vs. Steroids in Refractory Meniere’s Disease
NCT00879190	PHASE2/PHASE3	COMPLETED	Ampicillin / Sulbactam vs. Ampicillin / Gentamicin for Treatment of Chorioamnionitis
NCT01027429	PHASE3	COMPLETED	Simplified Antibiotic Therapy for Sepsis in Young Infants
NCT01244256	PHASE2/PHASE3	SUSPENDED	Efficacy and Comparative of the Association Beclomethasone Clotrimzaol + Gentamicin in Patients With Acne Contaminated
NCT01429701	PHASE3	COMPLETED	Effectiveness of Polymyxin B Sulphate + Prednisolone + Benzocaine + Clioquinol in Acute and Sub-acute Dermatitis Eczematous
NCT01551394	PHASE3	COMPLETED	Efficacy, Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days With Clinical or Confirmed Late-onset Sepsis
NCT01633294	PHASE2/PHASE3	COMPLETED	Antibiotic Prophylaxis in Prelabor Rupture of Membranes at Term

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

27 molecules share ≥1 primary target. Top 27 by shared-target count:

Molecule	Source	Status	Shared targets
TETRAHYDROCANNABIVARIN	ChEMBL	Phase 2	TRPA1, TRPV5
DICLOFENAC	ChEMBL + PubChem	Phase 4 (approved)	TRPA1
DISULFIRAM	ChEMBL + PubChem	Phase 4 (approved)	TRPA1
MEFENAMIC ACID	ChEMBL + PubChem	Phase 4 (approved)	TRPA1
MENTHOL	ChEMBL	Phase 4 (approved)	TRPA1
NICOTINE	ChEMBL	Phase 4 (approved)	TRPA1
RESVERATROL	ChEMBL + PubChem	Phase 3 (approved)	TRPA1
CANNABINOL	ChEMBL	Phase 3	TRPA1
ICILLIN	ChEMBL	Phase 3	TRPA1
LEVOMENTHOL	ChEMBL	Phase 3	TRPA1
ALLICIN	ChEMBL	Phase 2	TRPA1
CANNABIDIVARIN	ChEMBL	Phase 2	TRPA1
CANNABIGEROL	ChEMBL	Phase 2	TRPA1
CARVACROL	ChEMBL	Phase 2	TRPA1
CHLORDANTOIN	ChEMBL	Phase 2	TRPA1
FLUFENAMIC ACID	ChEMBL	Phase 2	TRPA1
RG6341	ChEMBL	Phase 2	TRPA1
SALIRASIB	ChEMBL	Phase 2	TRPA1
SANGUINARIUM	ChEMBL	Phase 2	TRPA1
THYMOL	ChEMBL	Phase 2	TRPA1
Acetaldehyde	PubChem	Approved	TRPA1
Caffeine	PubChem	Approved	TRPA1
camphor (synthetic)	PubChem	Approved	TRPA1
dronabinol	PubChem	Approved	TRPA1
Eugenol	PubChem	Approved	TRPA1
menthol, unspecified form	PubChem	Approved	TRPA1
Propylene Glycol	PubChem	Approved	TRPA1